135 related articles for article (PubMed ID: 11395572)
1. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.
Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG
Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
3. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
4. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial function, apoptosis and cell cycle delay in the WEHI-3B leukaemia cell line and its variant Ciprofloxacin-resistant WEHI-3B/CPX.
Pessina A; Bonomi A; Casati S; Collotta A; Croera C; Marafante E; Palitti F; Gribaldo L
Cell Prolif; 2007 Aug; 40(4):568-79. PubMed ID: 17635523
[TBL] [Abstract][Full Text] [Related]
6. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
7. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
Danks MK; Schmidt CA; Cirtain MC; Suttle DP; Beck WT
Biochemistry; 1988 Nov; 27(24):8861-9. PubMed ID: 2853972
[TBL] [Abstract][Full Text] [Related]
8. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
[TBL] [Abstract][Full Text] [Related]
10. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
11. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
13. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
15. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
16. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
18. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
[TBL] [Abstract][Full Text] [Related]
19. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to Cholera Toxin (CT)-induced apoptosis.
Pessina A; Croera C; Savalli N; Bonomi A; Cavicchini L; Turlizzi E; Guizzardi F; Guido L; Daprai L; Neri MG
Cell Res; 2006 Mar; 16(3):306-12. PubMed ID: 16541129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
